Filing Details

Accession Number:
0001535264-25-000015
Form Type:
13G Filing
Publication Date:
2025-02-13 19:00:00
Filed By:
AWM Investment Company, Inc.
Company:
Oncocyte Corp (NYSE:OCX)
Filing Date:
2025-02-14
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
AWM Investment Company, Inc. 0 1,306,309 7.5%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G



Comment for Type of Reporting Person:  AWM Investment Company, Inc., a Delaware corporation (AWM), is the investment adviser to Special Situations Cayman Fund, L.P. (CAYMAN), Special Situations Fund III QP, L.P. (SSFQP), Special Situations Private Equity Fund, L.P. (SSPE) and Special Situations Life Sciences Fund, L.P. (SSLS). (the Funds). As the investment adviser to the Funds, AWM holds sole voting and investment power over 179,725 shares of Common Stock of the Issuer (the Shares) 77,434 Pre-Funded Warrants* and 656,661 Warrants* to purchase 32,833 Shares of Common Stock held by CAYMAN, 596,079 Shares, 265,454 Pre-Funded Warrants* and 2,345,216 Warrants* to purchase 117,261 Shares of Common Stock held by SSFQP, 375,234 Warrants* to purchase 18,762 Shares of Common Stock held by SSPE, and 375,234 Warrants* to purchase 18,762 Shares of Common Stock held by SSLS. * The Warrants described herein may only be exercised to the extent that the total number of Common Shares then beneficially owned does not exceed 9.99% of the outstanding shares


SCHEDULE 13G


 
AWM Investment Company, Inc.
 
Signature:Adam Stettner
Name/Title:Executive Vice President
Date:12/31/2024